Expertise in
6
conditions

Dr. Mansoor Saleh

Hematology
1100 Johnson Ferry Rd Ne, Suite 600, 
Sandy Springs, GA 
Expertise in
6
conditions
1100 Johnson Ferry Rd Ne, Suite 600, 
Sandy Springs, GA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Mansoor Saleh is a Hematologist in Sandy Springs, Georgia. Dr. Saleh is highly rated in 6 conditions, according to our data. His top areas of expertise are Immune Thrombocytopenic Purpura (ITP), Purpura, Adult Immune Thrombocytopenia, Thrombocytopenia, and Splenectomy.

His clinical research consists of co-authoring 68 peer reviewed articles and participating in 7 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology
Licenses
Internal Medicine in GA
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO

Locations

1100 Johnson Ferry Rd Ne, Suite 600, Sandy Springs, GA 30342

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

A Phase 1 Study of LY3434172, a Bispecific Antibody Monotherapy in Advanced Solid Tumors
A Phase 1 Study of LY3434172, a Bispecific Antibody Monotherapy in Advanced Solid Tumors
Enrollment Status: Terminated
Publish Date: January 15, 2025
Intervention Type: Drug
Study Phase: Phase 1
A Phase 1b/2 Dose Escalation and Cohort Expansion Study of the Safety, Tolerability and Efficacy of a Novel Transforming Growth Factor-beta Receptor I Kinase Inhibitor (Galunisertib) Administered in Combination With Anti-PD-1 (Nivolumab) in Advanced Refractory Solid Tumors (Phase 1b) and in Recurrent or Refractory Non-small Cell Lung Cancer or Hepatocellular Carcinoma (Phase 2)
A Phase 1b/2 Dose Escalation and Cohort Expansion Study of the Safety, Tolerability and Efficacy of a Novel Transforming Growth Factor-beta Receptor I Kinase Inhibitor (Galunisertib) Administered in Combination With Anti-PD-1 (Nivolumab) in Advanced Refractory Solid Tumors (Phase 1b) and in Recurrent or Refractory Non-small Cell Lung Cancer or Hepatocellular Carcinoma (Phase 2)
Enrollment Status: Completed
Publish Date: September 09, 2021
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
An Open-label Phase 1/2A Study To Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of TRC253, an Androgen Receptor Antagonist, in Patients With Metastatic Castration-resistant Prostate Cancer
An Open-label Phase 1/2A Study To Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of TRC253, an Androgen Receptor Antagonist, in Patients With Metastatic Castration-resistant Prostate Cancer
Enrollment Status: Completed
Publish Date: April 23, 2021
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
Phase 2 Multicenter, Open-Label Study of CS-1008, A Humanized Monoclonal Antibody Targeting Death Receptor 5 (DR5), In Combination With Gemcitabine in Chemotherapy Naive Subjects With Unresectable or Metastatic Pancreatic Cancer
Phase 2 Multicenter, Open-Label Study of CS-1008, A Humanized Monoclonal Antibody Targeting Death Receptor 5 (DR5), In Combination With Gemcitabine in Chemotherapy Naive Subjects With Unresectable or Metastatic Pancreatic Cancer
Enrollment Status: Completed
Publish Date: April 08, 2021
Intervention Type: Drug
Study Phase: Phase 2
A Phase 1, Open-Label, Dose-Escalation and Expansion, Safety and Tolerability Study of INCB062079 in Subjects With Advanced Hepatocellular Carcinoma and Other Malignancies
A Phase 1, Open-Label, Dose-Escalation and Expansion, Safety and Tolerability Study of INCB062079 in Subjects With Advanced Hepatocellular Carcinoma and Other Malignancies
Enrollment Status: Terminated
Publish Date: July 15, 2020
Intervention Type: Drug
Study Phase: Phase 1
An Open-Label, Phase 1a/1b Study of Ramucirumab in Combination With Other Targeted Agents in Advanced Cancers
An Open-Label, Phase 1a/1b Study of Ramucirumab in Combination With Other Targeted Agents in Advanced Cancers
Enrollment Status: Completed
Publish Date: March 05, 2019
Intervention Type: Drug
Study Phase: Phase 1
View 5 Less Clinical Trials

68 Total Publications

Insights Into Cancer Awareness and Health Practices in Rural Kenya: A Cross-Sectional Study of Esophageal, Breast, Prostate, Cervical, and Colorectal Cancers.
Insights Into Cancer Awareness and Health Practices in Rural Kenya: A Cross-Sectional Study of Esophageal, Breast, Prostate, Cervical, and Colorectal Cancers.
Journal: JCO global oncology
Published: May 09, 2025
Similar Doctors
Expertise in
10
conditions
Dr. Lakshmanan Krishnamurti
Hematology | Oncology
Expertise in
10
conditions
Dr. Lakshmanan Krishnamurti
Hematology | Oncology
1405 Clifton Rd Ne, 
Atlanta, GA 
 (6.9 miles away)
404-785-1112
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Lakshmanan Krishnamurti is a Hematologist and an Oncologist in Atlanta, Georgia. Dr. Krishnamurti is highly rated in 10 conditions, according to our data. His top areas of expertise are Sickle Cell Disease, Hemoglobinopathy, Congenital Hemolytic Anemia, Hemolytic Anemia, and Bone Marrow Transplant. Dr. Krishnamurti is currently accepting new patients.

Christine L. Kempton
Expertise in
21
conditions
Dr. Christine L. Kempton
Hematology
Expertise in
21
conditions
Dr. Christine L. Kempton
Hematology

Emory Hemophilia Of Georgia

550 Peachtree Street Northeast, MedicalOfficeTower, 
Atlanta, GA 
 (7.7 miles away)
404-778-1900
Experience:
29+ years
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Christine Kempton is a Hematologist in Atlanta, Georgia. Dr. Kempton has been practicing medicine for over 29 years is highly rated in 21 conditions, according to our data. Her top areas of expertise are Hemophilia A, Blood Clots, Hemophilia B, Von Willebrand Disease (VWD), and Bone Marrow Aspiration.

Expertise in
27
conditions
Dr. Martha L. Arellano
Hematology | Oncology
Expertise in
27
conditions
Dr. Martha L. Arellano
Hematology | Oncology

Emory Medical Care Foundation Inc

80 Jesse Hill Jr Dr Se, 
Atlanta, GA 
 (9.0 miles away)
404-616-1000
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Martha Arellano is a Hematologist and an Oncologist in Atlanta, Georgia. Dr. Arellano is highly rated in 27 conditions, according to our data. Her top areas of expertise are Acute Myeloid Leukemia (AML), Acute Promyelocytic Leukemia, Acute Lymphoblastic Leukemia (ALL), Bone Marrow Aspiration, and Bone Marrow Transplant. Dr. Arellano is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Saleh's expertise for a condition
ConditionClose
    View All 43 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile